頭頸鱗狀細胞癌市場：KOL 洞察

本報告考察了全球頭頸鱗狀細胞癌市場，並提供了市場概述，包括已上市的治療方法、管道趨勢和未來前景。

目錄

執行摘要

目前與未來的治療演算法

研究目的

PD-1/L1抑制劑

• 核准的藥物
  • Keytruda（pembrolizumab，Merck & Co.）
  • Opdivo（納武單抗，Bristol Myers Squibb）
  • Loctorzi（tripalimab、Coherus/Junshi）
• 正在研究藥物
  • Tecentriq（atezolizumab，Roche）

新的免疫療法

• 正在研究藥物
  • HPV 治療性疫苗（ISA Pharmaceuticals、PDS Biotechnology、BioNTech）
  • Multikine（白血球介素；CEL-SCI）
  • CUE-101（Cue Biopharma）

標靶治療

• 正在研究藥物
  • Zebina Panto（Debio 1143；Merck Group）
  • ASP-1929（西妥昔單抗 salotarocan，Rakuten Medical）
  • AN2025（buparlisib；Adlai Nortye）
  • 替比法尼（Kura Oncology）
  • 抗體藥物偶聯物（例如 Padsev（enfortumab vedotin，Astellas/Pfizer）、Kadcyla（曲妥珠單抗 emtansine，Roche））

HNSCC的未來趨勢

• 主要見解摘要

附錄

What underpins KOLs' views that novel strategies combining PD-1 therapies with bispecifics, ADCs and HPV-directed vaccines could disrupt first-line and later-line therapy in R/M HNSCC? How do experts assess the potential of Merck Group's inhibitor-of-apoptosis proteins antagonist xevinapant in the treatment of LA-HNSCC? KOLs critically assess the prospects of launched and pipeline therapies.

Companies Listed:

Table of Contents

Executive summary (9)

Current and future treatment algorithm (1)

Research objectives (3)

PD-1/L1 inhibitors (40)

• Approved drugs (31)
  • Keytruda (pembrolizumab; Merck & Co.) (9)
  • Opdivo (nivolumab; Bristol Myers Squibb) (13)
  • Loqtorzi (toripalimab; Coherus/Junshi) (9)
• Pipeline drugs (9)
  • Tecentriq (atezolizumab; Roche) (9)

Novel immunotherapies (25)

• Pipeline drugs (25)
  • HPV therapeutic vaccines (ISA Pharmaceuticals; PDS Biotechnology; BioNTech) (11)
  • Multikine (leukocyte interleukin; CEL-SCI) (7)
  • CUE-101 (Cue Biopharma) (7)

Targeted therapies (42)

• Pipeline drugs (42)
  • Xevinapant (Debio 1143; Merck Group) (9)
  • ASP-1929 (cetuximab sarotalocan; Rakuten Medical) (10)
  • AN2025 (buparlisib; Adlai Nortye) (7)
  • Tipifarnib (Kura Oncology) (9)
  • Antibody-drug conjugates (e.g. Padcev [enfortumab vedotin; Astellas/Pfizer]; Kadcyla [trastuzumab emtansine; Roche]) (7)

Future trends in HNSCC (13)

• Key insights summary (13)

Appendix (5)

• KOL details (5)
  • KOLs from the USA (2)
  • KOLs from Europe (2)